Christoph Bruening
Corporate Officer/Principal bei Value Relations GmbH
Profil
Christoph Bruening has been a Director of Callisto Pharmaceuticals, Inc. since May 2003.
He is a Managing Partner of Value Relations GmbH and a Member of the Advisory board of Clarity AG.
Mr. Bruening was Funds Manager and Director-Asset Management of Value Management and Research AG from 1998 to 1999.
He was a Financial Analyst and Head-Research of Value Research GmbH from 1997 to 1998.
Aktive Positionen von Christoph Bruening
| Unternehmen | Position | Beginn |
|---|---|---|
| Value Relations GmbH | Corporate Officer/Principal | 01.01.1999 |
Ehemalige bekannte Positionen von Christoph Bruening
| Unternehmen | Position | Ende |
|---|---|---|
Callisto Pharmaceuticals, Inc.
 Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | Direktor/Vorstandsmitglied | 26.05.2010 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | Health Technology |
| Value Relations GmbH |
